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Abstract
In Europe, the number of antiepileptic drugs (AEDs) licensed for dogs has grown considerably over the last years.
Nevertheless, the same questions remain, which include, 1) when to start treatment, 2) which drug is best used
initially, 3) which adjunctive AED can be advised if treatment with the initial drug is unsatisfactory, and 4) when
treatment changes should be considered. In this consensus proposal, an overview is given on the aim of AED
treatment, when to start long-term treatment in canine epilepsy and which veterinary AEDs are currently in use for
dogs. The consensus proposal for drug treatment protocols, 1) is based on current published evidence-based literature,
2) considers the current legal framework of the cascade regulation for the prescription of veterinary drugs in Europe,
and 3) reflects the authors’ experience. With this paper it is aimed to provide a consensus for the management of
canine idiopathic epilepsy. Furthermore, for the management of structural epilepsy AEDs are inevitable in addition
to treating the underlying cause, if possible.
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Background
In Europe, the number of antiepileptic drugs (AEDs) li-
censed for dogs has grown considerably over the last
years. Nevertheless, the same questions remain, which
include, 1) when to start treatment, 2) which drug is best
used initially, 3) which adjunctive AED can be advised if
treatment with the initial drug is unsatisfactory, and 4)
when treatment changes should be considered. In this
consensus proposal, an overview is given on the aim of
AED treatment, when to start long-term treatment in
canine epilepsy and which veterinary AEDs are currently
in use for dogs. The consensus proposal for drug treatment
protocols, 1) is based on current published evidence-based
literature [17], 2) considers the current legal framework of
the cascade regulation for the prescription of veterinary
drugs in Europe, and 3) reflects the authors’ experience.
With this paper it is aimed to provide a consensus for the
management of canine idiopathic epilepsy. Furthermore,
for the management of structural epilepsy AEDs are in-
evitable in addition to treating the underlying cause, if
possible.
At present, there is no doubt that the administration
of AEDs is the mainstay of therapy. In fact, the term
AED is rather inappropriate as the mode of action of
most AEDs is to suppress epileptic seizures, not epilep-
togenesis or the pathophysiological mechanisms of epi-
lepsy. Perhaps, in the future, the term anti-seizure drugs
might be more applicable in veterinary neurology, a term
that is increasingly used in human epilepsy. Additionally,
it is known that epileptic seizure frequency appears to
increase over time in a subpopulation of dogs with un-
treated idiopathic epilepsy, reflecting the need of AED
treatment in these patients [63].
In our consensus proposal on classification and termin-
ology we have defined idiopathic epilepsy as a disease in
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its own right, per se. A genetic origin of idiopathic epilepsy
is supported by genetic testing (when available) and a gen-
etic influence is supported by a high breed prevalence
(>2 %), genealogical analysis and /or familial accumulation
of epileptic individuals. However in the clinical setting
idiopathic epilepsy remains most commonly a diagnosis of
exclusion following diagnostic investigations for causes of
reactive seizures and structural epilepsy.
Aims of AED treatment
The ideal goal of AED therapy is to balance the ability
to eliminate epileptic seizures with the quality of life of
the patient. Seizure eradication is often not likely in
dogs. More realistic goals are to decrease seizure fre-
quency, duration, severity and the total number of epi-
leptic seizures that occur over a short time span, with
no or limited and acceptable AED adverse effects to
maximize the dog’s and owner’s quality of life. Clinicians
should approach treatment using the following paradigm
[23, 76, 91, 92, 120]:
– Decide when to start AED treatment
– Choose the most appropriate AED and dosage
– Know if and when to monitor serum AED
concentrations and adjust treatment accordingly
– Know when to add or change to a different AED
– Promote pet owner compliance
When to recommend maintenance AED treatment?
Definitive, evidence-based data on when to start AED
therapy in dogs based on seizure frequency and type is
lacking. As such, extrapolation from human medicine may
be possible to provide treatment guidelines. Clinicians
should consider the general health of the patient, as well
as the owner’s lifestyle, financial limitations, and comfort
with the proposed therapeutic regimen. Individualized
therapy is paramount for choosing a treatment plan. As a
general rule, the authors recommend initiation of long-
term treatment in dogs with idiopathic epilepsy when any
one of the following criteria is present:
– Interictal period of ≤ 6 months (i.e. 2 or more
epileptic seizures within a 6 month period)
– Status epilepticus or cluster seizures
– The postictal signs are considered especially
severe (e.g. aggression, blindness) or last longer
than 24 hours
– The epileptic seizure frequency and/or duration
is increasing and/or seizure severity is
deteriorating over 3 interictal periods
In humans, the decision regarding when to recommend
AED treatment is based on a number of risk factors
(e.g. risk of recurrence, seizure type, tolerability, adverse
effects) [42, 115]. In people, clear proof exists that there is
no benefit initiating AED treatment after a single unpro-
voked seizure [42], but there is evidence to support start-
ing treatment after the second seizure [43, 108]. In dogs,
long-term seizure management is thought to be most suc-
cessful when appropriate AED therapy is started early in
the course of the disease, especially in dogs with a high
seizure density and in dog breeds known to suffer from a
severe form of epilepsy [12−14]. A total number of ≥ 10
seizures during the first 6 months of the disease appeared
to be correlated with a poor outcome in Australian Shep-
herds with idiopathic epilepsy [132]. Furthermore, recent
evidence exists that seizure density is a crucial risk factor,
experiencing cluster seizures, and being male is associated
with poor AED response [84].
A strong correlation exists in epileptic people between
a high seizure frequency prior to AED treatment and
poor AED response [16, 34, 59]. Historically, this has
been attributed to kindling, in which seizure activity
leads to intensification of subsequent seizures [117].
However, there is little clinical evidence that kindling
plays a role in either dogs [54] or humans [111] with re-
current seizures. In humans, a multifactorial pathogen-
esis is suggested [14, 52]. Recent epidemiologic data
suggest that there are differences in the intrinsic severity
of epilepsy among individuals, and these differences in-
fluence a patient’s response to medication and long-term
outcome. Additionally, evidence for seizure-associated
alterations that affect the pharmacodynamics and
pharmacokinetics of AEDs have been suggested [99].
Breed-related differences in epilepsy severity have been
described in dogs, with a moderate to severe clinical
course reported in Australian Shepherds [132], Border
Collies [49, 84], Italian Spinoni [24], German Shepherds
and Staffordshire Bull Terriers [84], whereas a less se-
vere form of the disease has been described in a different
cohort of Collies (mainly rough coated) [77], Labrador
Retrievers [7] and Belgian Shepherds [45]. Consequently,
genetics may affect the success of treatment and may ex-
plain why some breeds are more predisposed to drug re-
sistant epilepsy [3, 77].
Choice of AED therapy
There are no evidence-based guidelines regarding the
choice of AEDs in dogs. When choosing an AED for the
management of epilepsy in dogs several factors need to
be taken into account (AED-specific factors (e.g. regula-
tory aspects, safety, tolerability, adverse effects, drug inter-
actions, frequency of administration), dog-related factors
(e.g. seizure type, frequency and aetiology, underlying
pathologies such as kidney/hepatic/gastrointestinal prob-
lems) and owner-related factors (e.g. lifestyle, financial cir-
cumstances)) [23]. In the end, however, AED choice is
often determined on a case-by-case basis.
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Until recently, primary treatment options for dogs
with epilepsy have focused mainly on phenobarbital (PB)
and potassium bromide (KBr) due to their long standing
history, widespread availability, and low cost. While both
AEDs are still widely used in veterinary practice, several
newer AEDs approved for use in people are also being
used for the management of canine idiopathic epilepsy
mainly as add-on treatment. Moreover, since early 2013,
imepitoin has been introduced in most European coun-
tries for the management of recurrent single generalized
epileptic seizures in dogs with idiopathic epilepsy.
Several AEDs of the older generation approved for
humans have been shown to be unsuitable for use in
dogs as most have an elimination half-life that is too
short to allow convenient dosing by owners, these in-
clude phenytoin, carbamazepine, valproic acid, and etho-
suximide [119]. Some are even toxic in dogs such as
lamotrigine (the metabolite is cardiotoxic) [26, 136] and
vigabatrin (associated with neurotoxicity and haemolytic
anemia) [113, 131, 138].
Since the 1990s, new AEDs with improved tolerability,
fewer side effects and reduced drug interaction potential
have been approved for the management of epilepsy in
humans. Many of these novel drugs appear to be rela-
tively safe in dogs, these include levetiracetam, zonisa-
mide, felbamate, topiramate, gabapentin, and pregabalin.
Pharmacokinetic studies on lacosamide [68] and rufina-
mide [137] support the potential use of these drugs in
dogs, but they have not been evaluated in the clinical
setting. Although these newer drugs have gained consid-
erable popularity in the management of canine epilepsy,
scientific data on their safety and efficacy are very lim-
ited and cost is often prohibitive.
Phenobarbital
Efficacy
PB has the longest history of chronic use of all AEDs in
veterinary medicine. After decades of use, it has been
approved in 2009 for the prevention of seizures caused
by generalized epilepsy in dogs. PB has a favourable
pharmacokinetic profile and is relatively safe [2, 87, 97].
PB seems to be effective in decreasing seizure frequency
in approximately 60−93 % of dogs with idiopathic epi-
lepsy when plasma concentrations are maintained within
the therapeutic range of 25−35 mg/l [10, 31, 74, 105].
According to Charalambous et al. (2014) [17], there is
overall good evidence for recommending the use of PB
as a monotherapy AED in dogs with idiopathic epilepsy.
Moreover, the superior efficacy of PB was demonstrated
in a randomized clinical trial comparing PB to bromide
(Br) as first-line AED in dogs, in which 85 % of dogs ad-
ministered PB became seizure-free for 6 months com-
pared with 52 % of dogs administered Br [10]. This
study demonstrated a higher efficacy of PB compared to
Br as a monotherapy, providing better seizure control
and showing fewer side effects.
Pharmacokinetics
PB is rapidly (within 2h) absorbed after oral administra-
tion in dogs, with a reported bioavailability of approxi-
mately 90 % [2, 87]. Peak serum concentrations are
achieved approximately 4−8h after oral administration in
dogs [2, 97]. The initial elimination half-life in normal
dogs has been reported to range from 37−73h after mul-
tiple oral dosing [96]. Plasma protein binding is approxi-
mately 45 % in dogs [36]. PB crosses the placenta and
can be teratogenic.
PB is metabolized primarily by hepatic microsomal en-
zymes and approximately 25 % is excreted unchanged in
the urine. There is individual variability in PB absorption,
excretion and elimination half-life [2, 87, 97]. In dogs, PB
is a potent inducer of cytochrome P450 enzyme activity in
the liver [48], and this significantly increases hepatic pro-
duction of reactive oxygen species, thus increasing the risk
of hepatic injury [107]. Therefore PB is contraindicated in
dogs with hepatic dysfunction. The induction of cyto-
chrome P450 activity in the liver can lead to autoinduction
or accelerated clearance of itself over time, also known as
metabolic tolerance, as well as endogenous compounds
(such as thyroid hormones) [40, 48]. As a result, with
chronic PB administration in dogs, its total body clearance
increases and elimination half-life decreases progressively
which stabilizes between 30−45 days after starting therapy
[97]. This can result in reduction of PB serum concen-
trations and therapeutic failure and therefore, monitor-
ing of serum PB concentrations is very important for
dose modulation over time.
A parenteral form of PB is available for intramuscular
(IM) or intravenous (IV) administration. Different PB
formulations are available in different countries, it should
be emphasized, however, that IM formulations cannot be
used IV and vice versa. Parenteral administration of PB is
useful for administering maintenance therapy in hospital-
ized patients that are unable to take oral medication. The
pharmacokinetics of IM PB have not been explored in
dogs, however, studies in humans have shown a similar
absorption after IM administration compared to oral ad-
ministration [135]. The elimination half-life in dogs after a
single IV dose is approximately 93h [87].
Pharmacokinetic interactions
In dogs, chronic PB administration can affect the dispos-
ition of other co-administered medications which are me-
tabolized by cytochrome P450 subfamilies and/or bound
to plasma proteins [48]. PB can alter the pharmacokinetics
and as a consequence may decrease the therapeutic ef-
fect of other AEDs (levetiracetam, zonisamide, and ben-
zodiazepines) as well as corticosteroids, cyclosporine,
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metronidazole, voriconazole, digoxin, digitoxin, phenyl-
butazone and some anaesthetics (e.g. thiopental) [23, 33,
72, 82, 130]. As diazepam is used as first-line medicine for
emergency use (e.g. status epilepticus) in practice it should
be emphasized to double the IV or rectal dose of diazepam
in dogs treated chronically with PB [130]. Concurrent ad-
ministration of PB and medications that inhibit hepatic
microsomal cytochrome P450 enzymes such as cimetidine,
omeprazole, lansoprazole, chloramphenicol, trimethoprim,
fluoroquinolones, tetracyclines, ketoconazole, fluconazole,
itraconazole, fluoxetine, felbamate and topiramate may
inhibit PB metabolism, increase serum concentration and
can result in toxicity [10].
Common adverse effects
Most of the adverse effects due to PB are dose dependent,
occur early after treatment initiation or dose increase and
generally disappear or decrease in the subsequent weeks due
to development of pharmacokinetic and pharmacodynamic
tolerance [35, 121] (Table 1). The adverse effects include
sedation, ataxia, polyphagia, polydipsia and polyuria. For an
in-depth review on the adverse effects of PB, the reader is
referred to comprehensive book chapters [23, 32, 91].
Idiosyncratic adverse effects
These effects occur uncommonly in dogs and include
hepatotoxicity [13, 22, 39, 75], haematologic abnormalities
(anaemia, and/or thrombocytopenia, and/or neutropenia)
[51, 56]), superficial necrolytic dermatitis [66], potential
risk for pancreatitis [38, 46], dyskinesia [58], anxiety [58],
and hypoalbuminaemia [41] (Table 1). Most of these
idiosyncratic reactions are potentially reversible with dis-
continuation of PB. For an in-depth review on the idiosyn-
cratic adverse effects of PB the reader is referred to
comprehensive book chapters [23, 32, 91].
Laboratory changes
Laboratory changes related to chronic PB administration in
dogs include elevation in serum liver enzyme activities [39,
41, 75], cholesterol and triglyceride concentrations [41]. Alter-
ations in some endocrine function testing may occur (thyroid
and adrenal function, pituitary-adrenal axis) [21, 41, 128]. For
an in-depth review on these laboratory changes the reader is
referred to comprehensive book chapters [23, 32, 91].
Dose and monitoring (Fig. 1)
The recommended oral starting dose of PB in dogs is
2.5−3 mg/kg BID. Subsequently, the oral dosage is tailored
Table 1 Most common reported adverse effects seen in dogs treated with PB, imepitoin and KBr (rarely reported and/or
idiosyncratic adverse effects are indicated in grey





Imepitoin Polyphagia (often transient)
KBr Sedation
Ataxia and pelvic limb weakness
Polydipsia/polyuria
Polyphagia
Nausea, vomiting and/or diarrhea
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to the individual patient based on seizure control, adverse
effects and serum concentration monitoring.
Because of considerable variability in the pharmaco-
kinetics of PB among individuals, the serum concentra-
tion should be measured 14 days after starting therapy
(baseline concentration for future adjustments) or after
a change in dose. To evaluate the effect of metabolic
tolerance, a second PB serum concentration can be
measured 6 weeks after initiation of therapy. Recom-
mendations on optimal timing of blood collection for
serum PB concentration monitoring in dogs vary among
studies [23]. Generally, serum concentrations can be
checked at any time in the dosing cycle as the change
in PB concentrations through a daily dosing interval is
not therapeutically relevant once steady-state has been
achieved [62, 70]. However, in dogs receiving a dose of
5 mg/kg BID or higher, trough concentrations were sig-
nificantly lower than non-trough concentrations and
serum PB concentration monitoring at the same time
post-drug dosing was recommended, in order to allow
accurate comparison of results in these dogs [70]. Another
study recommended performing serum PB concentration
monitoring on a trough sample as a significant difference
between peak and trough PB concentration was identified
in individual dogs [10]. The therapeutic range of PB in
serum is 15 mg/l to 40 mg/l in dogs. However, it is the au-
thors’ opinion that in the majority of dogs a serum PB
concentration between 25−30 mg/l is required for optimal
seizure control. Serum concentrations of more than 35
mg/l are associated with an increased risk of hepatotoxicity
and should be avoided [22, 75]. In case of inadequate seiz-
ure control, serum PB concentrations must be used to
guide increases in drug dose. Dose adjustments can be cal-
culated according to the following formula (Formula A):
New PB total daily dosage in mg
¼ desired serum PB concentration=actual serum PB concentrationð Þ
 actual PB total daily dosage in mg
A dog with adequate seizure control, but serum drug
concentrations below the reported therapeutic range,
does not require alteration of the drug dose, as this
serum concentration may be sufficient for that individ-
ual. Generally, the desired serum AED concentration for
individual patients should be the lowest possible concen-
tration associated with >50 % reduction in seizure fre-
quency or seizure-freedom and absence of intolerable
adverse effects [23].
In animals with cluster seizures, status epilepticus or
high seizure frequency, PB can be administered at a
loading dose of 15−20 mg/kg IV, IM or PO divided in
multiple doses of 3−5 mg/kg over 24−48h to obtain a
therapeutic brain concentration quickly and then sustain
it [10]. Serum PB concentrations can be measured 1−3
days after loading. Some authors load as soon as possible
(over 40 to 60 min) and start with a loading dose of 10
to 12 mg/kg IV followed by two further boluses of 4 to 6
mg/kg 20 min apart.
Complete blood cell count, biochemical profile (includ-
ing cholesterol and triglycerides), and bile acid stimulation
Fig. 1 PB treatment flow diagram for decision making during seizure management in an otherwise healthy dog. The authors advise to start with
PB (and add KBr if inadequate seizure control after optimal use of PB (Fig. 3)): in dogs with idiopathic epilepsy experiencing recurrent single
generalised epileptic seizures; in dogs with idiopathic epilepsy experiencing cluster seizures or status epilepticus; in dogs with other epilepsy
types. *Criteria for (in)adequate seizure control with regard to efficacy and tolerability (see Consensus proposal: Outcome of therapeutic
interventions in canine and feline epilepsy [94]). 1. Treatment efficacious: a: Achievement of complete treatment success (i.e. seizure freedom or
extension of the interseizure interval to three times the longest pretreatment interseizure interval and for a minimum of three months (ideally > 1
year); b: Achievement of partial treatment success (i.e. a reduction in seizure frequency including information on seizure incidence (usually at least
50 % or more reduction defines a drug responder), a reduction in seizure severity, or a reduction in frequency of seizure clusters and/or status
epilepticus). 2. Treatment not tolerated i.e. appearance of severe adverse effects necessitating discontinuation of the AED
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test should be performed before starting PB treatment and
periodically at 3 months and then every 6 months during
treatment. In case of adequate seizure control, serum PB
concentrations should be monitored every 6 months. If
the dog is in remission or has no seizures, a periodical
control every 12 months is advised.
Imepitoin
Efficacy
Imepitoin was initially developed as a new AED for
humans, but, the more favourable pharmacokinetic profile
of imepitoin in dogs versus humans led to the decision to
develop imepitoin for the treatment of canine idiopathic
epilepsy [102]. Based on randomized controlled trials that
demonstrated antiepileptic efficacy, high tolerability and
safety in epileptic dogs, the drug was approved in 2013 for
this indication in Europe [64, 98, 122]. It has been recom-
mended to use imepitoin in dogs with idiopathic epilepsy
experiencing recurrent single generalized epileptic sei-
zures, however, its efficacy has not yet been demonstrated
in dogs with cluster seizures or status epilepticus [30]. In a
recent randomized controlled study [122], the efficacy of
imepitoin was compared with PB in 226 client-owned
dogs. The administration of imepitoin twice daily in incre-
mental doses of 10, 20 or 30 mg/kg demonstrated that the
majority of dogs with idiopathic epilepsy were managed
successfully with imepitoin without significant difference
to the efficacy of PB. The frequency of adverse events (e.g.
sedation, polydipsia, polyphagia) was significantly higher
in the PB group [122]. In a study by Rieck et al. (2006)
[98], dogs with chronic epilepsy not responding to PB or
primidone received imepitoin (in its initial formulation) or
KBr as adjunct AED and the seizure frequency improved
to a similar degree in both groups. According to Chara-
lambous et al. (2014) [17], there is good evidence for
recommending the use of imepitoin as monotherapy in
dogs with recurrent single generalized epileptic seizures,
but insufficient evidence for use as adjunct AED. At
present, scientific data and evidence-based guidelines on
which AED can best be combined with imepitoin are lack-
ing, and further research is needed. Nevertheless, at this
moment, the authors recommend the use of PB as adjunct
AED in dogs receiving the maximum dose of imepitoin
and experiencing poor seizure control. According to the
authors, in case of combined therapy with imepitoin and
PB, it is advised to slowly wean off imepitoin over several
months if seizure control appears successful on PB and/or
to reduce the dose of imepitoin if adverse effects (e.g. sed-
ation) occur (Fig. 2).
Pharmacokinetics
Following oral administration of imepitoin at a dose of
30 mg/kg in healthy Beagle dogs, high plasma levels
were observed within 30 min, but maximal plasma levels
were only reached after 2−3h following a prolonged ab-
sorption time [101]. The elimination half-life was found
to be short; approximately 1.5 to 2h. However, in an-
other study in Beagle dogs, a longer half-life (~6 h) was
found after higher doses of imepitoin, and accumulation
of plasma levels was seen during chronic BID treatment
[64]. Also, it has to be considered that Beagle dogs elim-
inate AEDs more rapidly than other dog strains [122].
Despite the short half-life in healthy Beagle dogs, this
pharmacokinetic profile is reported as adequate to main-
tain therapeutically active concentrations with twice
daily dosing in dogs [64, 122]. Imepitoin is extensively
metabolized in the liver prior to elimination. In dogs,
imepitoin is mainly excreted via the faecal route rather
than the urinary route. Neither reduced kidney function
nor impaired liver function is likely to greatly influence
the pharmacokinetics of imepitoin [122].
Pharmacokinetic interactions and adverse reactions
There is no information on pharmacokinetic interactions
between imepitoin and other medications. Although,
imepitoin is a low affinity partial agonist for the benzodi-
azepine binding site of the GABAA receptor it has not
prevented the pharmacological activity of full benzodi-
azepine agonists such as diazepam in the clinical setting
(e.g. in dogs with status epilepticus) [122]. Consequently,
because the affinity of diazepam for the GABAA receptor
is much higher than imepitoin, care should be taken in
the emergency setting [122]. Therefore, dogs with idio-
pathic epilepsy treated with imepitoin and presented in
status epilepticus might require, in addition to diazepam,
an additional AED parenterally (e.g. PB, levetiracetam).
Mild and most commonly transient adverse reactions
(Table 1) have been reported in dogs administered 10−30
mg/kg BID of imepitoin in its initial formulation; polypha-
gia at the beginning of the treatment, hyperactivity,
polyuria, polydipsia, somnolence, hypersalivation, em-
esis, ataxia, lethargy, diarrhoea, prolapsed nictitating mem-
branes, decreased vision and sensitivity to sound [64, 98].
As part of the development of imepitoin for the treat-
ment of canine epilepsy, a target animal safety study in
dogs was conducted [96]. Under laboratory conditions,
healthy Beagle dogs were exposed to high doses (up to
150 mg/kg q12h) of imepitoin for 6 months. Clinical
signs of toxicity were mild and infrequent and they were
mostly CNS (depression, transient ataxia) or gastrointes-
tinal system (vomiting, body weight loss, salivation) re-
lated. These clinical signs were not life-threatening and
generally resolved within 24h if symptomatic treatment
was given. These data indicate that imepitoin is a safe
AED and is well tolerated up to high doses in dogs
treated twice daily [96]. However, the safety of imepitoin
has not been evaluated in dogs weighing less than 5 kg
or in dogs with safety concerns such as renal, liver,
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cardiac, gastrointestinal or other disease. No idiosyncratic
reactions have been demonstrated so far. The routinely
measured liver enzymes’ activity do not appear to be in-
duced by imepitoin [96]. Compared with the traditional
benzodiazepines, such as diazepam, which acts as full ago-
nists at the benzodiazepine site of the GABAA receptor,
partial agonists such as imepitoin show less sedative ad-
verse effects and are not associated with tolerance and
dependence during long-term administration in animal
models [122]. Also in epileptic dogs, tolerance did not
develop and no withdrawal signs were observed after
treatment discontinuation [64].
Dose and monitoring (Fig. 2)
The oral dose range of imepitoin is 10−30 mg/kg BID.
The recommended oral starting dose of imepitoin is 10−20
mg/kg BID. If seizure control is not satisfactory after at
least 1 week of treatment at this dose and the medica-
tion is well tolerated, the dose can be increased up to a
maximum of 30 mg/kg BID. Reference range of plasma
or serum imepitoin concentrations is unknown and
there are no therapeutic monitoring recommendations
for imepitoin from the manufacturer. Pharmacokinetic
studies in dogs suggest variability in plasma imepitoin
concentrations among individuals and sampling times.
However, no correlation between plasma imepitoin con-
centration and seizure frequency reduction was identified
[64] therefore and because of its wide therapeutic index,
serum imepitoin monitoring is not needed.
The authors recommend a complete blood cell count
and biochemical profile before starting imepitoin treat-
ment and periodically every 6 months during treatment.
If the dog is in remission or has no seizures, a periodical
control every 12 months is advised.
Bromide
Efficacy
Br is usually administered as the potassium salt (KBr).
The sodium salt form (NaBr) contains more Br per gram
of compound, therefore, the dose should be approxi-
mately 15 % less than that calculated for KBr [124]. In
most EU countries, KBr is approved only for add-on
treatment in dogs with epilepsy drug-resistant to first-
line AED therapy. PB and KBr have a synergistic effect
and add-on treatment with KBr in epileptic dogs im-
proves seizure control in dogs that are poorly controlled
with PB alone [46, 93, 126]. A recent study showed that
Fig. 2 Imepitoin treatment flow diagram for decision making during seizure management in an otherwise healthy dog. The authors advise to
start with imepitoin in dogs with idiopathic epilepsy experiencing recurrent single generalised epileptic seizures. *Criteria for (in)adequate seizure
control with regard to efficacy and tolerability (see Consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy [94]).
1. Treatment efficacious: a: Achievement of complete treatment success (i.e. seizure freedom or extension of the interseizure interval to three
times the longest pretreatment interseizure interval and for a minimum of three months (ideally > 1 year), b: Achievement of partial treatment
success (i.e. a reduction in seizure frequency including information on seizure incidence (usually at least 50 % or more reduction defines a drug
responder), a reduction in seizure severity, or a reduction in frequency of seizure clusters and/or status epilepticus). 2. Treatment not tolerated i.e.
appearance of severe adverse effects necessitating discontinuation of the AED. #Currently there are no data available on which AED should be
added to imepitoin in case of inadequate seizure control. At this moment, the authors recommend the use of PB as adjunct AED in dogs
receiving the maximum dose of imepitoin and experiencing poor seizure control
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KBr was less efficacious and tolerable than PB as first-
line drug [10]. According to Charalambous et al. (2014)
[17] there is fair level of evidence for recommending the
use of KBr as a monotherapy, but less as adjunct AED.
Pharmacokinetics
The bioavailability of Br after oral administration in nor-
mal dogs is approximately 46 %. The elimination half-life
is long and ranges from 25−46 days in dogs, consequently,
it can take several months (approximately 3 months) be-
fore steady-state concentrations after treatment initiation
at maintenance dose are reached [46, 67, 90, 125]. KBr is
unbound to plasma proteins and can diffuse freely across
cellular membranes. KBr is not metabolised in the liver
and is therefore a good alternative in dogs with hepatic
dysfunction. KBr is excreted unchanged in the urine and
undergoes tubular reabsorption in competition with chlor-
ide. Therefore, dietary factors affecting chloride levels can
alter serum KBr concentrations [123]. High (low) dietary
chloride concentrations increase (decrease) the excretion
of KBr and shorten (prolong) its half-life. Dogs adminis-
tered KBr should be maintained on a constant diet (and
chloride intake) to prevent fluctuations in serum KBr
concentrations, which could result in therapeutic fail-
ure or toxicity. If dietary changes are necessary they
should be made gradually (over at least 5 days) and
serum concentrations of KBr should be monitored fol-
lowing dietary changes, especially if the dog becomes
sedated or has unexpected seizures. On biochemistry
profiles serum chloride concentrations are often falsely
elevated (“pseudohyperchloraemia”) because the assays
cannot distinguish between chloride and Br ions [123].
Pharmacokinetic interactions and adverse effects
Pharmacokinetic interactions of KBr are limited as KBr
is not metabolized or protein-bound. The main interac-
tions are associated with alterations in the renal excretion
of KBr. As already mentioned, the rate of elimination of
KBr varies proportionally and inversely to chloride intake.
Loop diuretics such as furosemide may enhance KBr elim-
ination by blocking KBr reabsorption through renal tubu-
lar chloride channels. KBr should be avoided in dogs with
renal dysfunction to prevent toxicity secondary to reduced
renal elimination [80].
Common, dose-dependent adverse effects of KBr in
dogs include sedation, ataxia and pelvic limb weakness,
polydipsia/polyuria, and polyphagia with weight gain
[4, 25, 46, 124] (Table 1). These effects occur in the
initial weeks of treatment and may be magnified by
concurrent PB administration. These adverse effects
subside (partly or completely), once KBr steady-state
concentrations are reached [125]. Gastrointestinal
irritation and clinical signs can be prevented or
minimized by administering Br with food and dividing
the daily dose into 2 or more doses [4].
Uncommon idiosyncratic reactions of KBr in dogs in-
clude personality changes (aggressive behaviour, irritabil-
ity, hyperactivity), persistent cough, increased risk of
pancreatitis and megaoesofagus [4, 46, 67, 106] (Table 1).
Kbr may cause skin problems (bromoderma) in humans
[106], but no reports exist currently in dogs. For an in-
depth review on the adverse effects of Br the reader is
referred to comprehensive book chapters [23, 32, 91].
Dose and monitoring (Fig. 3)
The recommended oral starting dose of KBr is 15 mg/
kg BID when used as an add-on drug. An oral dose of
20 mg/kg BID is advised when used as a monotherapy.
Because of the long elimination half-life, KBr can be ad-
ministered once daily (preferably in the evening), however,
twice daily dosing as well as administration with food can
help to prevent gastrointestinal mucosa irritation [123].
Twice daily dosing is also recommended if excessive sed-
ation is present. Therapeutic ranges have been reported as
approximately 1000 mg/l to 2000 mg/l when administered
in conjunction with PB and 2000mg/l to 3000mg/l when
administered alone [126]. Br has a long half-life, conse-
quently, reaching a steady-state serum concentration may
require several months (approximately 3 months). Due to
this long half-life, timing of blood sample collection rela-
tive to oral administration is not critical [123].
Baseline complete blood cell count, biochemical profile
(including cholesterol and triglycerides) should be per-
formed before starting KBr treatment and periodically
every 6 months during treatment. Serum KBr concen-
trations should be monitored 3 months after treatment
initiation (or dose change). In the long term, in dogs
with adequate seizure control, serum KBr concentra-
tions should be monitored every 6 months. If the dog is
in remission or has no seizures, a periodical control
every 12 months is advised.
A loading dose may be recommended to achieve steady-
state therapeutic concentrations more rapidly (e.g. in dogs
with frequent or severe seizures, or when PB must be rap-
idly discontinued because of life-threatening adverse ef-
fects). Different protocols have been reported. Oral loading
can be performed by administering KBr at a dose of 625
mg/kg given over 48h and divided into eight or more
doses. A more gradual loading can be accomplished giving
125 mg/kg/day divided in three to four daily administra-
tions for 5 consecutive days. Daily phone contact with the
owners is advised. Loading can be associated with adverse
effects (e.g. nausea, vomiting, diarrhoea, sedation, ataxia
and pelvic limb weakness, polydipsia, polyuria and poly-
phagia) and the dog should be hospitalized if loading takes
place over 48h (7,85). It is advised to stop loading when
serious adverse effects occur. Consider that dogs in which
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KBr is used as adjunct AED to PB may be more prone to
adverse effects. In these cases, a PB dose decrease of 25 %
may be needed. Serum KBr levels should be monitored 1
month after loading.
Dose increases can be calculated according to the fol-
lowing formula
Formula B:
For concomitant PB and KBr treatment, the new main-
tenance dose can be calculated as follows:
2000 mg=l ‐ actual serum KBr steady‐state concentrationð Þ  0:02
¼ mg=kg=day added to existing dose
Formula C:
In case of monotherapy KBr, the new maintenance
dose can be calculated as follows:
2500 mg=l − actual serum KBr steady−state concentrationð Þ
 0:02 ¼ mg=kg=day added to existing dose
Only PB and imepitoin are approved as first-line treat-
ment of canine epilepsy in the EU. In most EU coun-
tries, KBr is only approved as add-on treatment in dogs
resistant to first-line treatments. None of the drugs
discussed in the following section are approved for treat-
ment of dogs with epilepsy, thus, according to EU drug
laws, these drugs can only be used as adjunctive treat-
ment if monotherapy or polytherapy with the approved
treatments have failed. Furthermore, except for levetirac-
etam, none of the AEDs discussed in the following sec-
tion have been evaluated in randomized controlled trials
in epileptic dogs, so that the evidence for their efficacy is
very limited [17].
Levetiracetam
So far, three studies evaluated the efficacy of levetirace-
tam as an adjunct to other AEDs [79, 114, 127]. In all
these studies, the majority of the dogs were treated suc-
cessfully by oral levetiracetam as adjunct AED. The use
of oral levetiracetam was evaluated in an open-label
study and a response rate of 57 % was reported in dogs
with drug resistant epilepsy [127]. In a recent random-
ized placebo-controlled study by Muñana et al. (2012)
[79], the use of levetiracetam was evaluated in dogs with
drug resistant epilepsy. A significant decrease in seizure
frequency was reported compared with baseline, however,
no difference was detected in seizure frequency when
Fig. 3 KBr adjunct treatment flow diagram for decision making during seizure management in an otherwise healthy dog. *Criteria for (in)adequate
seizure control with regard to efficacy and tolerability (see Consensus proposal: Outcome of therapeutic interventions in canine and feline epilepsy
[94]). 1. Treatment efficacious: a: Achievement of complete treatment success (i.e. seizure freedom or extension of the interseizure interval to three
times the longest pretreatment interseizure interval and for a minimum of three months (ideally > 1 year), b: Achievement of partial treatment success
(i.e. a reduction in seizure frequency including information on seizure incidence (usually at least 50 % or more reduction defines a drug responder), a
reduction in seizure severity, or a reduction in frequency of seizure clusters and/or status epilepticus). 2. Treatment not tolerated i.e. appearance of
severe adverse effects necessitating discontinuation of the AED
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levetiractam was compared with placebo. However, the di-
vergence in group size and the small sample size (due to
the high dropout rate) may have contributed to this result.
Nevertheless, a trend towards a decrease in seizure fre-
quency and increase in responder rate during levetirace-
tam administration compared to placebo warrants further
evaluation in a larger scale study. According to the study
of Charalambous et al., (2014) [17], there is a fair evidence
for recommending the use of levetiracetam as an adjunct
AED. Recently, a retrospective study provided further evi-
dence that administering levetiracetam as an adjunct AED
is well tolerated, and suppresses epileptic seizures signifi-
cantly in dogs with idiopathic epilepsy [83]. The authors
also confirmed that if seizure frequency increases, an extra
AED may be beneficial and they added the possibility of
administering levetiracetam as pulse treatment for cluster
seizures.
Levetiracetam possesses a favourable pharmacokinetic
profile in dogs with respect to its use as an add-on AED.
It has rapid and complete absorption after oral adminis-
tration, minimal protein binding, minimal hepatic metab-
olism and is excreted mainly unchanged via the kidneys.
In humans and dogs, renal clearance of levetiracetam is
progressively reduced in patients with increasing severity
of renal dysfunction [85], thus, dosage reduction should
be considered in patients with impaired renal function. As
levetiracetam has minimal hepatic metabolism [85], this
drug represents a useful therapeutic option in animals
with known or suspected hepatic dysfunction. However,
its short elimination half-life of 3−6 h necessitates fre-
quent administration. The recommended oral mainten-
ance dose of levetiracetam in dogs is 20 mg/kg TID-QID.
The same dose can be administered parenterally in dogs
(SC, IM, IV) when oral administration is not possible [86].
In a previous study [127] it was shown that some dogs de-
velop a tolerance to levetiracetam when used chronically.
This phenomenon, the ‘honeymoon effect’, has been docu-
mented for other AEDs, e.g. zonisamide and levetiracetam
in dogs with epilepsy [127, 129]. Therefore, the introduc-
tion of the pulse treatment protocol (an initial dose of 60
mg/kg orally or parenterally after a seizure occurs or pre-
ictal signs are recognized by the owner, followed by 20
mg/kg TID until seizures do not occur for 48h) was devel-
oped, in order to start treatment only in case of cluster
seizures when therapeutic levetiracetam concentrations
need to be reached rapidly. The results in the recent study
by Packer et al., 2015 [83] supports this clinical approach.
Pulse treatment was, however, associated with more side
effects compared to maintenance levetiracetam therapy
[83]. Levetiracetam is well tolerated and generally safe in
dogs. Except for mild sedation, ataxia, decreased appetite
and vomiting adverse effects are very rarely described in
dogs [79, 127] (Table 2). Levetiracetam has also a different
mode of action compared to other AEDs and therefore
may be advantageous when polytherapy is instituted.
It selectively binds to a presynaptic protein (SVA2),
whereby it seems to modulate the release of neuro-
transmitters [86]. As, in dogs there is no information
available regarding a therapeutic range [79], the human
target range of 12−46 μg/l can be used as guidance regard-
ing effective concentrations.
Studies in humans have shown that concomitant admin-
istration of AEDs that induce cytochrome P450 metabol-
ism such as PB, can alter the disposition of levetiracetam
[19]. Recently, it has been demonstrated that PB ad-
ministration significantly alters the pharmacokinetics of
levetiracetam in normal dogs [73]. Thus, levetiracetam
oral dose may need to be increased or dosing time
interval may need to be shortened when concurrently
administered with PB [73]. Also in dogs with epilepsy,
concurrent administration of PB alone or in combination
with KBr increases levetiracetam clearance compared to
concurrent administration of KBr alone [78]. Thus, dosage
increases might be indicated when utilizing levetiracetam
as add-on treatment with PB in dogs [78], preferably guided
by levetiracetam serum concentration measurement.
Table 2 Most common reported adverse effects seen in dogs
treated with levetiracetam, zonisamide, felbamate, topiramate,
gabapentin, and pregabalin (rarely reported and/or idiosyncratic
adverse effects are indicated in grey
AED Adverse effects in dogs
Levetiracetam Sedation
Ataxia
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Zonisamide
There are few reports on the use of zonisamide in dogs,
despite it being licensed for treatment of canine epilepsy
in Japan. One report evaluated the efficacy of oral zonisa-
mide as a monotherapy [18]. Two studies have been de-
scribed evaluating zonisamide as an add-on treatment in
dogs with drug resistant epilepsy [28, 129]. Based on the
results of these studies, Charalambous et al. (2014) [17]
concluded that, at present, there is insufficient evidence to
recommend the use of zonisamide either as a monotherapy
or as an adjunct AED in dogs. Larger studies are required
to evaluate zonisamide as a monotherapy or as an adjunct-
ive AED in dogs. Adverse effects in dogs include sedation,
vomiting, ataxia, and loss of appetite [18, 28, 129] (Table 2).
Additionally, recently hepatotoxicity has been described in
2 dogs receiving zonisamide monotherapy which is be-
lieved to be an idiosyncratic reaction to the drug [69, 104]
(Table 2). Renal tubular acidosis has also been described in
a dog receiving zonisamide monotherapy [20] (Table 2).
Thus, zonisamide should be used with caution in dogs with
renal or hepatic impairment. Both, hepatic and renal fail-
ures have been described in humans receiving zonisamide
as well. Currently, zonisamide is not available in every
country and when available, it can be very expensive.
Zonisamide is a sulphonamide-based anticonvulsant
approved for use in humans. The exact mechanism of
action is unknown, however, blockage of calcium channels,
enhancement of GABA release, inhibition of glutamate
release, and inhibition of voltage-gated sodium channels
might contribute to its anticonvulsant properties [61]. In
dogs, zonisamide is well-absorbed after oral administration,
has a relatively long elimination half-life (approximately
15h), and has low protein binding so that drug interactions
are minimized. The drug mainly undergoes hepatic metab-
olism via the cytochrome P450 system before excretion by
the kidneys [11].
The recommended oral starting dose of zonisamide in
dogs is 3−7 mg/kg BID and 7−10 mg/kg BID in dogs co-
administered hepatic microsomal enzymes inducers such
as PB [11, 28]. Serum concentrations of zonisamide
should be measured minimally 1 week after treatment
initiation or dosage adjustment to allow steady state con-
centrations be reached. Care should be taken to avoid
haemolysis, as falsely elevated serum zonisamide concen-
trations from lysed red blood cells may occur. The human
target range of 10−40 mg/l can be used as guidance re-
garding effective concentrations. [28]. Baseline complete
blood cell count and biochemical profile should be per-
formed before starting zonisamide treatment and period-
ically every 6 months during treatment.
Felbamate
One veterinary study evaluated the efficacy of felbamate
as an adjunct to PB in 6 dogs with focal idiopathic
epilepsy [100]. According to Charalambous et al. (2014)
[17], the study demonstrated overall moderate/high risk
of bias. On this basis it was concluded that there is cur-
rently insufficient evidence to recommending the use of
felbamate as an add-on AED. Felbamate should be re-
served for dogs refractory to the other more thoroughly
investigated and safer AEDs in this species and as such
this is a 4th or 5th line option. In the clinical study by
Ruehlmann et al., (2001) [100] adverse effects noted in-
cluded keratoconjunctivitis sicca and mild blood dyscra-
sias (Table 2).
Felbamate is a dicarbamate AED released for use in
humans in 1993 for the control of focal seizures. Its
mechanism of action is multiple such as inhibition of
glycine-enhanced NMDA-induced intracellular calcium
currents [134], blockade of voltage-gated sodium channels
and inhibition of voltage –gated calcium currents [133].
In 1993, felbamate was marketed as a safe AED, which
lacked demonstrable toxic side effects and did not require
laboratory monitoring in humans. However, within a year
of its release it became evident that felbamate was associ-
ated with an unacceptable incidence of life-threatening
side effects [12], such as anorexia, weight loss, vomiting,
headache, irritability. Moreover, aplastic anemia and fatal
hepatotoxicity were also described [55, 134].
Pharmacokinetic interactions between felbamate and
other AEDs have been well described. E.g. felbamate
raises concurrent PB serum levels in a dose-dependent
manner [12], and the elimination of felbamate was noted
to be strikingly reduced when given with gabapentin
[50]. Felbamate is mainly metabolized by the liver [88]
and should therefore not be used in dogs with pre-
existing hepatic disease. Felbamate has an elimination
half-life of 5−7h.
The recommended oral starting dose in dogs is 20
mg/kg TID, increasing to 400−600mg/day every 1−2
weeks [1]. Haematologic evaluations and biochemistry
panels (esp. liver enzyme concentrations) should be per-
formed before felbamate therapy is initiated and during
therapy. This is especially important in animals receiving
concurrent PB. In humans, the signs of aplastic anaemia
and liver failure are usually seen during the first 6−12
months of therapy. In dogs, a minimum of monthly
blood tests should be performed for this period of time,
following-up every 6−12 months after this. Currently,
felbamate is not available in every country.
Topiramate
In 2013, one sudy evaluated the efficacy of topiramate as
an adjunct to PB, KBr, and levetiracetam in 10 dogs [57].
The dose was titrated (2−10 mg/kg) two to three times
daily. Sedation, ataxia and weight loss were the most
common adverse effects in dogs (Table 2). According to
Charalambous et al. (2014) [17], the study demontsrated
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an overall moderate/high risk of bias. Thus, there is cur-
rently insufficient evidence to recommend the use of
topiramate as an adjunct AED [17].
In humans, topiramate has served both as a monother-
apy and adjunctive therapy to treat focal and generalised
seizures [29, 71]. It is a sulphamate-substituted mono-
saccharide that acts on multiple signalling mechanisms
enhancing GABA-ergic activity and inhibiting voltage-
sensitive sodium and calcium channels, kainate-evoked
currents and carbonic anhydrase isoenzymes [118, 139].
From the available human data, topiramate is not metab-
olized extensively once absorbed, with 70−80 % of an ad-
ministered dose eliminated unchanged in the urine [65].
Topiramate has an elimination half-life of 2−4h. Clearance
of topiramate is reduced in patients with renal impairment,
necessitating dosage adjustments [37]. In dogs, topiramate
is not extensively metabolized and is primarily eliminated
unchanged in the urine. However, biliary excretion is
present following topiramate administration in dogs [15].
The drug has a relatively low potential for clinically relevant
interactions with other medications [8, 53]. The most com-
monly observed adverse effects in humans are somnolence,
dizziness, ataxia, vertigo and speech disorders [110]. No ad-
verse reactions were reported in healthy Beagle dogs ad-
ministered 10−150 mg/kg daily oral doses for 15 days [116].
Gabapentin
Two prospective studies evaluated the efficacy of oral
gabapentin as an adjunct to other AEDs, giving a combined
sample size of 28 dogs [44, 89]. According to Charalambous
et al. (2014) [17], one study demonstrated an overall mod-
erate/high risk of bias and the other one demonstrated an
overall high risk of bias. None of the studies demonstrated
an increased likelihood that the majority of the dogs were
treated successfully by oral administration of gabapentin.
Accordingly, there is currently overall insufficient evidence
for recommending the use of gabapentin as an adjunct
AED [17]. If used, the recommended oral dosage of gaba-
pentin in dogs is 10 to 20 mg/kg TID, although dose reduc-
tion may be necessary in patients with reduced renal
function [9]. Sedation and ataxia were the most common
side effects reported in dogs [44, 89] (Table 2).
Gabapentin has been approved in people in Europe
and by the US Food and Drug Administration (FDA)
since 1993 for adjunctive treatment of focal seizures with
or without secondary generalisation and for the treatment
of post-herpetic neuralgia [9]. Its precise mechanism of
action is unclear, but is believed that much of its anticon-
vulsant effect is because of its binding to a specific modu-
latory protein of voltage-gated calcium channels, which
results in decreased release of excitatory neurotransmit-
ters [112]. In humans, gabapentin is entirely excreted by
the kidneys. In dogs, renal excretion occurs after a partial
hepatic metabolism. The elimination half-life is 3−4h.
Although information in veterinary medicine is lim-
ited, pharmacokinetic interactions of gabapentin are un-
likely to occur as the drug has negligible protein binding
and does not induce hepatic cytochrome P450 family en-
zymes [95]. In humans, the elimination of felbamate was
noted to be significantly reduced when given with gaba-
pentin [50]. The most common adverse effects in humans
include dizziness, somnolence and fatigue [9]. These ef-
fects seem to be dose-dependent and resolve within the
first few weeks of treatment. No serious idiosyncratic reac-
tions or organ toxicities have been identified in humans or
animals [60].
Pregabalin
There is limited data on the use of pregabalin in dogs. In
a study by Dewey et al., (2009), the efficacy of oral preg-
abalin as an adjunct to PB and KBr was evaluated in 9
dogs [27]. According to Charalambous et al. (2014) [17],
this study demonstrated an overall moderate/high risk of
bias. Consequently, there is currently insufficient evi-
dence to recommend the use of pregabalin as an adjunct
AED [17]. If used, the recommended oral dose in dogs is
3−4 mg/kg BID-TID. The most common adverse effects
(Table 2) in the study of Dewey et al., (2009) included
sedation, ataxia and weakness, and to minimize these,
treatment could be initiated at a dose of 2 mg/kg two to
three times daily and escalated by 1 mg/kg each week
until the final dose is achieved [27]. As pregabalin clearance
is highly correlated with renal function, dose reduction is
necessary in patients with reduced renal function [5, 9].
Pregabalin is a GABA analogue that is structurally
similar to gabapentin. Pregabalin was approved in 2004
for the treatment of adults with peripheral neuropathic
pain and as adjunctive treatment for adults with focal
seizures with or without secondary generalization. Preg-
abalin is more potent than gabapentin owing to a greater
affinity for its receptor [112]. Pharmacokinetic studies
have been performed in dogs, with a reported elimin-
ation half-life of approximately 7 h [103]. In humans,
pregabalin does not bind to plasma proteins and is ex-
creted virtually unchanged by the kidneys [9]. Pregabalin
does not undergo hepatic metabolism and does not in-
duce or inhibit hepatic enzymes such as the cytochrome
P450 system [5]. No clinically relevant pharmacokinetic
drug interactions have been identified in humans to
date. The most commonly reported adverse effects in
humans are dose-related and include dizziness, somno-
lence and ataxia [9].
Discontinuation of AEDs
Two main reasons for discontinuation of an AED are re-
mission of seizures or life-threatening adverse effects.
Generally, treatment for idiopathic epilepsy involves life-
long AED administration. However, remission has been
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reported in dogs. Remission rates between 15−30 % have
been described in hospital based populations [6, 7, 47, 49].
In a study by Packer et al. (2014) 14 % of dogs were in re-
mission on PB [84]. When ≥50 % reduction in seizure fre-
quency was used as the outcome measure, success rates
were markedly higher with 64,5 % of dogs achieving this
level of seizure reduction. Several factors were associated
with an increased likelihood of achieving remission, namely:
being female, neutered, no previous experience of cluster
seizures and an older age at onset of seizures. The same
four factors were associated with an increased likelihood of
achieving a ≥50 % reduction in seizure frequency [84]. The
breed least likely to go into remission or have an ≥50 %
reduction in seizure frequency was the Border Collie (0
and 40 %, respectively), the German Shepherd (11 and
35 %, respectively) and Staffordshire Bull Terrier (0 and
57 %, respectively) [84]. In a study by Hülsmeyer et al.
(2010) the remission rate was 18 % in Border Collies
independent of disease severity [49]. The decision to
gradually taper the dose of an AED should be taken on
a case-by-case basis, but seizure freedom of at least 1−2
years is advised. In people with prolonged seizure re-
mission (generally 2 or more years), the decision to dis-
continue AED treatment is done on an individual basis
considering relative risks and benefits. Individuals with
the highest probability of remaining seizure-free are
those who had no structural brain lesion, a short dur-
ation of epilepsy, few seizures before pharmacological
control, and AED monotherapy [81, 109]. In dogs, how-
ever, little information on risk factors associated with
seizure relapse exist, thus the pet owner must be aware
that seizures may recur anytime during AED dose re-
duction of after discontinuation. To prevent withdrawal
seizures or status epilepticus it is advised to decrease
the dose with 20 % or less on a monthly basis.
In case of life-threatening adverse effects, instant ces-
sation of AED administration under 24h observation is
necessary. In these cases, loading with an alternative
AED should be initiated promptly in order to achieve
target serum concentrations before serum PB concentra-
tion decreases. Loading with KBr (see section on KBr) or
levetiracetam (see section on levetiracetam) is possible.
If hepatic function is normal, starting imepitoin or zoni-
samide at the recommended oral starting dose may be
another alternative.
Pet owner education
In order to promote a successful management of an epi-
leptic pet, owners need to be educated thoroughly on
[23, 32, 91]:
– The disease of their pet and the influence on their
daily life (considerations regarding e.g. leaving the
dog alone, what to do if travelling and leaving
the dog in a kennel, fears of behavioural
comorbidities, …)
– The need for AED therapy and the understanding
that this often is a lifetime commitment
– The aim of AED therapy
– The importance of regular administration of AEDs
– The fact that dose adjustments should only be made
after consulting a veterinarian
– Potential adverse effects of AED therapy
– The importance of maintaining a detailed seizure
diary
– The importance of regular check-ups to monitor
AED blood concentrations as well as haematology/
serum biochemistry where appropriate
– The need for treatment modulation to achieve
optimal seizure control
– The possibility of occurrence of status epilepticus
and cluster seizures and the administration of
additional AEDs at home
– Costs involved
– The fact that drug interactions might occur when
combined with other AEDs or non-AEDs
– The understanding that abrupt drug withdrawal
might be detrimental
– The fact that diet (e.g salt content), diarrhoea and
vomiting may affect the absorption of AEDs. It
should be advised to keep the diet constant or to
make changes gradually and seek veterinary advice if
gastrointestinal signs occur.
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